MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load.
about
Sieve analysis in HIV-1 vaccine efficacy trialsHIV-1 infections with multiple founders are associated with higher viral loads than infections with single foundersAdvancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.Challenges in the design of a T cell vaccine in the context of HIV-1 diversity.Pathogenesis and treatment of HIV infection: the cellular, the immune system and the neuroendocrine systems perspective.Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trialImpact of mutations in highly conserved amino acids of the HIV-1 Gag-p24 and Env-gp120 proteins on viral replication in different genetic backgrounds.A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by VectorizationNew prospects for a preventive HIV-1 vaccine.Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083Development of prophylactic vaccines against HIV-1.Lower Viral Loads and Slower CD4+ T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection.Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults.Advances in antiviral vaccine development.Adenoviral vector-based strategies against infectious disease and cancer.Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B.Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
P2860
Q26851376-D3AD82EC-8D7D-4BB4-BA74-90A4711368A7Q28606620-E9E7F857-E955-41E4-9F6A-742F4AAFC183Q33742529-DDD85A42-1F14-4ECF-9EDD-6403F1DD6D3AQ34057942-DA31C0F0-24FE-449A-AC26-8434CFA2B5EFQ34423446-EC80AD2A-9C41-48F0-85AC-C57FEF937A7BQ34650866-D5BB40CA-7576-4F2F-971F-C937A901CEB0Q35043417-1E5933E3-564B-4E56-9AE5-6AD06AA6BEC8Q35142729-D4F0352A-0C5B-421F-84A3-A0136C012572Q35593139-9FC402D8-4D86-49FC-BCA6-D1A8EAAA59DFQ36211653-7DD1E852-4151-4217-9F79-02A2BCCCA79EQ36223864-0B94981E-C5EF-4B0B-9B75-A58D82FC94B2Q36487887-CB3F94C6-5336-4D4B-A9E5-3DB3CDF7EA7DQ37042563-1BE3D4C9-8818-4A52-8B70-401A4E5307BEQ37074610-1115BA68-6533-45A7-B790-C7D217FB48CFQ37187509-FE7E9098-A5CF-4A2A-8D50-CA3CE3CE86A4Q37221660-ABFE5F1F-78FD-4ACE-8E26-8C6AA0E77CE3Q37292398-03DA77AC-DDA9-4A4A-81EE-9F749F4BF96DQ38814885-772E4BA4-330E-4F3E-A833-2BACF1FD9D40Q41929341-DBF73DF9-0A9E-4FE1-9CA6-C2D2A86176C4Q46633111-853FDA35-24E4-493B-9915-6686A1B06CC5Q52580309-61AD6064-40DA-44F4-A2CF-9E2C4CCC6694
P2860
MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
MRKAd5 HIV-1 Gag/Pol/Nef vacci ...... to the vaccine or viral load.
@ast
MRKAd5 HIV-1 Gag/Pol/Nef vacci ...... to the vaccine or viral load.
@en
MRKAd5 HIV-1 Gag/Pol/Nef vacci ...... to the vaccine or viral load.
@nl
type
label
MRKAd5 HIV-1 Gag/Pol/Nef vacci ...... to the vaccine or viral load.
@ast
MRKAd5 HIV-1 Gag/Pol/Nef vacci ...... to the vaccine or viral load.
@en
MRKAd5 HIV-1 Gag/Pol/Nef vacci ...... to the vaccine or viral load.
@nl
prefLabel
MRKAd5 HIV-1 Gag/Pol/Nef vacci ...... to the vaccine or viral load.
@ast
MRKAd5 HIV-1 Gag/Pol/Nef vacci ...... to the vaccine or viral load.
@en
MRKAd5 HIV-1 Gag/Pol/Nef vacci ...... to the vaccine or viral load.
@nl
P2093
P2860
P50
P1433
P1476
MRKAd5 HIV-1 Gag/Pol/Nef vacci ...... to the vaccine or viral load.
@en
P2093
Allan DeCamp
David P Friedrich
James I Mullins
Julian Wolfson
Morgane Rolland
Nicole Frahm
Paul Goepfert
Peter Gilbert
P2860
P304
P356
10.1371/JOURNAL.PONE.0043396
P407
P577
2012-08-27T00:00:00Z